Skip to main content
Equibles
TNYA logo

TNYA · Tenaya Therapeutics, Inc.

Track TNYA — free

Use TNYA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNYA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.58 +0.04 (+6.63%)
Rebalance outlook locked
Market Cap
$122.03M
Shares
224.23M
Volume · Oct 9 4.26M Avg daily vol (3M) 2.29M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.54 Open$0.53 Day$0.52–0.55 52W close$0.53–2.10 Avg vol 30d2.5M Short int22.9M · 10.2% float · 7.6d Short vol63% Last earningsJun 3, 2026 DataJul 2021–Oct 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$103.11M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-43.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+33.7%
Year over year · more shares
Price change (1Y)
-70.3%
Trailing year
Short interest
10.2%
Latest settlement · 7.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −19%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −30%
trailing
YTD return −24%
this year
Relative strength −39%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
3 of 101 funds reported for Sep 30 · net -1.5K sh shares
Insider flow Distributing
Net -$21.0K over 90 days · 100% sells
Short interest Rising
10.22% of float · ▲ +5.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
101 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Fair
EPS growth +55%
Y/Y
Free cash flow $-68.9M
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −75%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
3 of 101 funds reported for Sep 30 · net -1.5K sh shares
Insider flow Distributing
Net -$21.0K over 90 days · 100% sells
Short interest Rising
10.22% of float · ▲ +5.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
101 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $2
vs 200-day avg -26% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TNYA
Tenaya Therapeutics, Inc.
this stock
$122.03M -23.6% — — 10.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.8%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.1%
CSLLY
Csl Ltd
 $61.58B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
100
% held
24.1%
Reported
3 of 101
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
23
View
Short & Settlement
Short Interest Rising
Shares short
22.9M
Days to cover
7.6d
Change
+1.3M sh
View
Short Volume
Short vol %
63%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$1.5K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
65.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$21.0K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-90.6M
EPS diluted
$-0.59
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Aug 11, 2026
This year
15
View
Proposed Sales
Value
$15.8K
Shares
22.2K
Filed
Aug 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
TNYA -3.8% -16.1% -30.4% -9.8% -23.6%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -5.1% -18.2% -39.4% -11.3% -37.1%
Key facts CIK 1858848 CUSIP 87990A106 13F (30d) 4 filings 4 filers Visit website Investor relations